Company Interview / BCAL's key breast cancer test milestone

Jayne Shaw from BCAL Diagnostics (ASX: BDX) discusses the accreditation of their North Ryde Laboratory, calling it a significant milestone for commercialising their breast cancer blood test. Scheduled for a soft launch in Sydney by early 2025, this test aims to complement traditional mammographies.

BCAL Diagnostics (ASX: BDX) successfully raised $10 million in August, with plans to expand nationally and internationally, including the US. Jayne mentions ongoing collaborations with labs in North Carolina, Chicago, and Minneapolis to ensure a smooth rollout of the test in various markets.

The test offers a non-invasive alternative to mammography, especially benefiting women under 40. With an initial cost of $300, Jayne emphasises the potential of the test to stand alone eventually and highlights the company's commitment to making breast cancer detection more accessible.